Induction and Impact of Anti-Drug Responses Elicited by a Human Recombinant Coagulation Factor FXa


Journal

The AAPS journal
ISSN: 1550-7416
Titre abrégé: AAPS J
Pays: United States
ID NLM: 101223209

Informations de publication

Date de publication:
11 04 2019
Historique:
received: 02 01 2019
accepted: 22 03 2019
entrez: 13 4 2019
pubmed: 13 4 2019
medline: 3 3 2020
Statut: epublish

Résumé

This paper presents a systemic investigation of ADA development and ADA impact of a human coagulation factor in nonclinical species during drug development and provides insights into potential implications in human if a similar ADA occurs. FXa

Identifiants

pubmed: 30976993
doi: 10.1208/s12248-019-0324-z
pii: 10.1208/s12248-019-0324-z
doi:

Substances chimiques

Recombinant Proteins 0
Factor Xa EC 3.4.21.6

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

52

Références

Haemophilia. 2011 Jan;17(1):e172-82
pubmed: 20609014
Haemophilia. 2010 Mar;16(2):256-62
pubmed: 19878331
J Thromb Haemost. 2017 May;15(5):931-937
pubmed: 28294526
J Pharm Sci. 2017 Aug;106(8):2136-2143
pubmed: 28389265
Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):657-662
pubmed: 27913543
Lancet. 2003 Oct 11;362(9391):1184-91
pubmed: 14568740
Nat Rev Immunol. 2015 Mar;15(3):185-9
pubmed: 25677493
Trends Immunol. 2007 Nov;28(11):482-90
pubmed: 17964218
J Immunol Methods. 2008 Apr 20;333(1-2):1-9
pubmed: 18275969
J Interferon Cytokine Res. 2002 Feb;22(2):207-13
pubmed: 11911803
J Thromb Haemost. 2012 Oct;10(10):2194-6
pubmed: 22846047
Blood. 2011 Jan 6;117(1):290-8
pubmed: 20864578
Ther Adv Drug Saf. 2011 Jun;2(3):113-28
pubmed: 25083207
J Biol Chem. 2008 Jul 4;283(27):18627-35
pubmed: 18460471
Blood. 2007 Jun 1;109(11):4648-54
pubmed: 17289808

Auteurs

Chuenlei Parng (C)

Pfizer Biomedicine Design, Pharmacokinetics Pharmacodynamics Metabolism, 610 Main St., Cambridge, Massachusetts, 02139, USA. chuenlei.parng@pfizer.com.

Michael Bolt (M)

Pfizer Drug Safety Research and Development, Cambridge, Massachusetts, 02139, USA.

Debra D Pittman (DD)

Pfizer Rare Disease Research Unit, Cambridge, Massachusetts, 02139, USA.

Teresa Caiazzo (T)

Pfizer Biomedicine Design, Andover, Massachusetts, 01810, USA.

Lisa Dyleski (L)

Pfizer Biomedicine Design, Andover, Massachusetts, 01810, USA.

Boris Gorovits (B)

Pfizer Biomedicine Design, Andover, Massachusetts, 01810, USA.

Rob Webster (R)

Pfizer Biomedicine Design, Pharmacokinetics Pharmacodynamics Metabolism, 610 Main St., Cambridge, Massachusetts, 02139, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH